BioMed Nexus daily brief: 4 doses a year for myasthenia gravis

Livsayis Wins FDA Approval as First siRNA for Myasthenia Gravis

Table of Contents

The FDA approved Regeneron’s Livsayis, the first siRNA for generalized myasthenia gravis and the only treatment dosed four times a year, on November 18, 2026.

Last updated: November 19, 2026

The FDA approved Regeneron’s Livsayis (cemdisiran) on November 18, 2026 for generalized myasthenia gravis in adults with AChR antibodies. It is the first siRNA therapy for the disease and the only treatment dosed subcutaneously four times a year.

This page covers the Livsayis approval and the Phase 3 NIMBLE results, AstraZeneca’s Klygefa approval from Monday, the pricing of SELLAS’ $150.0 million offering, the FDA’s published rejection letter for ivonescimab, the day’s discovery deals, and the November 18 session.

What did the FDA approve Livsayis (cemdisiran) for?

The FDA approved Livsayis for generalized myasthenia gravis in adults who are AChR antibody positive, the predominant form of the disease. It is the first and only siRNA therapy in the indication and the only gMG treatment administered subcutaneously four times per year.

Regeneron announced the approval after the close on Wednesday, November 18, 2026. Cemdisiran is a small interfering RNA that degrades the messenger RNA encoding complement protein C5, cutting C5 production at the source rather than binding the circulating protein the way antibody C5 inhibitors do. Reduced C5 means less terminal complement activation at the neuromuscular junction, where complement damage drives the muscle weakness of myasthenia gravis.

The approval carries real access texture. The label includes a boxed warning for serious meningococcal infections, standard for medicines that shut down C5, and Livsayis is available only through a REMS program: prescribers must enroll, and patients need meningococcal vaccination at least two weeks before the first dose. The most common adverse reactions were injection site reactions, viral infections, and urinary tract infections. Regeneron licensed cemdisiran worldwide from Alnylam Pharmaceuticals and is solely responsible for development, manufacturing, and commercialization; the release did not disclose the economics. It is Regeneron’s first approved medicine in neurology and its first approved siRNA, per chief scientific officer George Yancopoulos. An EU decision is anticipated in the second half of 2027.

What did the Phase 3 NIMBLE trial show?

NIMBLE, which Regeneron calls the largest global interventional gMG trial conducted to date, showed a 2.3 point placebo adjusted improvement on the MG-ADL activities of daily living scale at week 24 (p=0.0005), with benefit emerging as early as two weeks and no waning across the three month dosing interval.

NIMBLE (week 24) Livsayis Placebo Difference
MG-ADL change from baseline −4.5 (SE 0.4) −2.2 (SE 0.5) 2.3 points, p=0.0005
MG-ADL responders (≥3 point gain) 76.6% 44.1% p<0.001
QMG change from baseline −4.2 (SE 0.6) −1.5 (SE 0.7) 2.8 points, p=0.0015
QMG responders (≥5 point gain) 48.4% 19.0% p<0.001

NIMBLE is an ongoing randomized, double blind, placebo controlled Phase 3 trial in AChR antibody positive gMG with four arms: Livsayis every three months, a C5 inhibiting monoclonal antibody every four weeks, the combination, and placebo. The release did not name the antibody, did not give per arm patient counts, and reported the primary comparison of Livsayis against placebo. The primary endpoint was MG-ADL change from baseline to week 24; QMG was the key secondary. Regeneron reported rapid onset, a 2.5 point MG-ADL improvement visible as early as two weeks, and scores maintained through week 24 with, in the release’s words, no indication of waning efficacy across the three month interval.

What did AstraZeneca’s Klygefa approval cover?

Two days before Livsayis, on Monday, November 16, the FDA approved AstraZeneca’s Klygefa (gefurulimab), a once weekly, self administered C5 inhibiting nanobody for the same population: adults with gMG who are AChR antibody positive. Two new C5 medicines entered the same disease in 72 hours.

Klygefa is a dual binding single domain antibody from Alexion, AstraZeneca Rare Disease: one arm binds C5, the other binds serum albumin to extend half life enough for weekly subcutaneous dosing by autoinjector. In the Phase 3 PREVAIL trial (ALXN1720-MG-301, NCT05556096; 260 patients in 20 countries), Klygefa improved MG-ADL by 1.6 points versus placebo at week 26 (95% CI −2.4 to −0.8, p<0.0001), with clinical improvement observed from week one. AstraZeneca described tolerability as consistent with the C5 class, citing eculizumab and ravulizumab; the most common treatment emergent adverse events were injection site reactions (12%), back pain (8%), and vomiting (5%). PREVAIL results were published in JAMA Neurology in July 2026. AstraZeneca estimates 98,500 people in the US are diagnosed with gMG, 81,000 of them AChR antibody positive. The source document is AstraZeneca’s November 16 release, filed as a 6-K exhibit; we did not fetch the US prescribing information, so label details beyond the release are not characterized here. Background on the approval is in our Klygefa approval explainer.

How do the new gMG treatments differ?

The two approvals attack the same protein with opposite delivery philosophies: Klygefa trades weekly self injection for autonomy, while Livsayis trades a REMS program and quarterly dosing for the lowest treatment burden in the disease. NIMBLE and PREVAIL were different trials, so their effect sizes are not comparable head to head.

Livsayis (Regeneron) Klygefa (AstraZeneca)
Modality siRNA silencing C5 production Dual binding nanobody blocking C5
Dosing Subcutaneous, four times a year Subcutaneous autoinjector, once weekly, self administered
Pivotal result (own trial, vs placebo) MG-ADL +2.3 points at week 24 (NIMBLE, p=0.0005) MG-ADL +1.6 points at week 26 (PREVAIL, p<0.0001)
Access Boxed warning; REMS restricted Release states no REMS details; label not reviewed here
Approved November 18, 2026 November 16, 2026

The caveat matters: cross trial comparisons of MG-ADL effect sizes are unreliable because populations, baselines, and concomitant therapy differ. What is directly comparable is the shape of the offering. AstraZeneca is deliberately flanking its own infused C5 franchise, eculizumab and ravulizumab, with a home administered weekly option before a competitor does it first. Regeneron, entering neurology for the first time, is betting that four clinic touches a year beats 52 self injections for a chronic disease in an often older population. Both now face argenx’s FcRn incumbent Vyvgart, which built the modern gMG market.

Why did SELLAS price its $150 million offering at $13.00?

SELLAS priced its underwritten public offering at $13.00 per share late Wednesday, 32.1% below Tuesday’s post data close of $19.15 and 27.6% below Wednesday’s close of $17.95 (our arithmetic). The deal held its $150.0 million size: 11,538,462 new shares, with closing expected November 20, 2026.

Term Detail
Price $13.00 per share
Shares 11,538,462 (all primary)
Gross proceeds $150.0 million
Overallotment 30 days, up to 1,730,769 additional shares (≈$22.5 million)
Banks J.P. Morgan and TD Cowen lead books; Mizuho bookrunner; A.G.P. and Maxim lead managers
Closing Expected November 20, 2026

The sequence: SELLAS reported the Phase 3 REGAL survival win in AML maintenance Tuesday morning (median overall survival 24.0 versus 14.7 months, a 41% reduction in risk of death), the stock rose 156.4%, and the company commenced the offering at 4:01 pm the same day. Pricing crossed at 9:59 pm ET Wednesday, after a bookbuilding session in which the stock slipped 6.3% to $17.95. Thursday is the first session with the clearing price public. The pricing release, off the automatically effective March 2026 shelf (S-3 333-294504), contained no use of proceeds language. For the trial data behind the offering, see our REGAL Phase 3 coverage. Measured against Monday’s pre data close of $7.47, $13.00 still represents 74.0% more per share than the market would pay before the survival data existed (our arithmetic throughout).

What did the FDA’s published letter on ivonescimab say?

The FDA this week posted the complete response letter it sent Summit Therapeutics on ivonescimab, dated November 13, to its public CRL database. Per BioPharma Dive’s report of the letter, the agency called the benefits modest, said they do not outweigh additive safety risks, and told Summit a new trial would be needed.

The letter’s publication, reported by BioPharma Dive and STAT on Wednesday, came within days of the decision itself, which Summit disclosed on Sunday, November 15 with the framing that the FDA wanted a clear overall survival benefit. The letter as reported goes further: concerns about the size of the progression benefit, questions about relevance to US patients, and an instruction that a new application without new evidence would be unlikely to succeed. Leerink Partners analyst Daina Graybosch wrote, per the same report, that a resubmission on its own is unlikely to change the approval outcome. We did not retrieve the letter PDF itself; all characterizations here are attributed to the trade reports of it. Summit closed at $10.50 Wednesday, down 36.9% from its November 11 close (our arithmetic). Our decision coverage from Monday is at Ivonescimab CRL: FDA Demands a Significant Survival Win.

What deals did Eli Lilly and Biogen announce?

Two discovery stage alliances crossed Wednesday, per BioPharma Dive: Eli Lilly signed a cancer collaboration with Stipple Bio worth up to $5.9 billion, and Biogen paid more than $32 million upfront to Trimtech Therapeutics for CNS penetrant protein degraders, with up to $411 million in milestones.

Lilly’s deal uses Stipple’s technology to find molecules binding epitopes present only on tumor cells. Lilly will make an undisclosed upfront payment and an equity investment; the $5.9 billion figure is the biobucks ceiling, and the companies did not disclose the guaranteed portion. Biogen’s Trimtech agreement covers small molecule degraders designed to clear toxic protein aggregates in neurodegenerative disease, with Biogen holding an option to exclusive licenses. Neither deal had a company release in our sweep tonight; figures are attributed to BioPharma Dive. The structure is the 2026 deal market in miniature: modest guaranteed cash, large contingent totals, and big pharma buying discovery optionality rather than assets.

Which stocks moved on November 18, 2026?

SELLAS fell 6.3% during the bookbuild before pricing crossed after hours. Merck fell 3.9% in its first session after killing the nemtabrutinib program, on a soft large cap pharma tape. All closes are settled exchange closes; percentages are our arithmetic against Tuesday’s closes.

Ticker Close (Nov 18) Move Context
SLS $17.95 −6.3% Bookbuild session; $13.00 pricing crossed after the close
MRK $137.78 −3.9% First session after the nemtabrutinib discontinuation; sector tape also soft (LLY −2.3%)
CRBP $2.745 −8.8% Third straight decline; now 18.7% below Monday’s data day close
RYTM $119.04 +2.1% Second session higher after TRANSCEND long term extension data
GSK $48.58 −1.3% ADR; first session after the Nelkarmi accelerated approval

Context: XBI closed at $145.04, down 0.2%; SPY closed at $730.20, down 0.3%. Regeneron closed at $945.53, down 1.3%, before the Livsayis announcement; Thursday is the first reaction session. The same applies to Teva (R&D chief departure, 5:00 pm) and InspireMD (first US commercial TCAR procedures, 4:30 pm). GSK’s Nelkarmi, approved ten days early on Tuesday, is covered in our Nelkarmi approval explainer.

Frequently asked questions

What is Livsayis?

Livsayis (cemdisiran) is a small interfering RNA therapy from Regeneron, approved by the FDA on November 18, 2026 for generalized myasthenia gravis in adults who are AChR antibody positive. It silences production of complement protein C5.

How often is Livsayis dosed?

Livsayis is injected subcutaneously four times per year, once every three months. It is the only FDA approved gMG treatment with quarterly dosing.

What is cemdisiran’s mechanism of action?

Cemdisiran is an siRNA that degrades the messenger RNA encoding C5, blocking production of the protein, lowering circulating C5, and inhibiting terminal complement activation, which drives damage at the neuromuscular junction in myasthenia gravis.

What were the NIMBLE trial results?

At week 24, Livsayis improved MG-ADL by 4.5 points versus 2.2 for placebo, a 2.3 point placebo adjusted benefit (p=0.0005). 76.6% of Livsayis patients gained at least 3 MG-ADL points versus 44.1% on placebo. QMG improved 2.8 points versus placebo (p=0.0015).

Does Livsayis have a boxed warning?

Yes. The label carries a boxed warning for serious meningococcal infections, and the drug is available only through a REMS program requiring prescriber enrollment and meningococcal vaccination at least two weeks before the first dose.

Who makes Livsayis and where did it come from?

Regeneron develops, manufactures, and commercializes Livsayis under a worldwide license from Alnylam Pharmaceuticals, which discovered cemdisiran. It is Regeneron’s first approved neurology medicine and its first approved siRNA. Deal economics were not disclosed in the approval release.

What is Klygefa and when was it approved?

Klygefa (gefurulimab) is AstraZeneca’s once weekly, self administered C5 inhibiting nanobody, approved by the FDA on November 16, 2026 for adults with generalized myasthenia gravis who are AChR antibody positive.

What did the PREVAIL trial show for Klygefa?

In the 260 patient Phase 3 PREVAIL trial, Klygefa improved MG-ADL by 1.6 points versus placebo at week 26 (95% CI −2.4 to −0.8, p<0.0001), with improvement observed from week one. Results were published in JAMA Neurology in July 2026.

Is Livsayis better than Klygefa?

No head to head data exist. NIMBLE and PREVAIL were separate trials with different populations and durations, so their placebo adjusted MG-ADL gains (2.3 and 1.6 points) cannot be compared directly. The practical differences are dosing burden, self administration, and access requirements.

What price did SELLAS’ offering clear at?

SELLAS priced 11,538,462 shares at $13.00 on November 18, 2026 for $150.0 million gross, 32.1% below Tuesday’s $19.15 close and 27.6% below Wednesday’s $17.95 close (our arithmetic). Closing is expected November 20.

Why did SELLAS sell stock right after positive Phase 3 data?

The REGAL survival win moved SELLAS from $7.47 to $19.15 in one session, and the company commenced a $150.0 million offering the same day. Pricing at $13.00 captured part of the gain; it is still 74.0% above the pre data price (our arithmetic). The release did not state use of proceeds.

Did the FDA really publish Summit’s rejection letter?

Yes, per BioPharma Dive and STAT: the FDA posted the complete response letter for ivonescimab, dated November 13, 2026, to its public CRL database this week. We did not retrieve the PDF; characterizations are attributed to those reports.

What does the ivonescimab letter mean for Summit?

As reported, the FDA called the benefits modest relative to additive safety risks and indicated a new trial is needed, which pushes any US approval years out. Leerink’s Daina Graybosch wrote that a resubmission alone is unlikely to change the outcome (attributed).

How big is the Lilly and Stipple Bio deal?

Up to $5.9 billion in total value, per BioPharma Dive, built on an undisclosed upfront payment and an equity investment. The collaboration targets epitopes found only on tumor cells. No company release was retrieved in our sweep.

How many people have generalized myasthenia gravis in the US?

AstraZeneca estimates 98,500 people in the US are diagnosed with gMG, about 81,000 of them AChR antibody positive. Regeneron’s release cites roughly 85,000 Americans living with myasthenia gravis. Both are company figures.

Sources

Primary sources, November 16 to 18, 2026: Regeneron press release, November 18, 2026 (Livsayis FDA approval, NIMBLE results); AstraZeneca press release, November 16, 2026, filed as a Form 6-K exhibit with the SEC (Klygefa approval, PREVAIL results); SELLAS Life Sciences pricing release via GlobeNewswire, November 18, 2026 (offering terms); SELLAS launch release, November 17, 2026 (offering commencement). Settled closing prices from exchange close data.

Trade press, attributed: BioPharma Dive, November 18, 2026 (ivonescimab complete response letter contents; Lilly and Stipple Bio terms; Biogen and Trimtech terms; Leerink commentary); STAT, November 18, 2026 (CRL letter publication). The ivonescimab letter PDF itself was not retrieved for this article.

Related coverage

Featured Articles

Join 65,000+ Biotech, MedTech, and Pharma Leaders

Your Daily Edge in Biotech, MedTech, and Pharma

Get trusted, high-signal updates every morning
Breakthroughs, trial data, deals, and the news that matters